Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2001 to 2050 of 3030 results for all

  1. Fallopian tube recanalisation by guidewire (HTG44)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.

  2. Our partners

    NICE's partners

  3. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  4. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  5. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  6. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)

    Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

  7. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  8. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (HTG730)

    Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.

  9. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  10. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

  11. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

  12. Perioperative care in adults (QS216)

    This quality standard covers care in adults during the preoperative, intraoperative and postoperative periods. It describes high-quality care in priority areas for improvement.

  13. Percutaneous vertebroplasty (HTG3)

    Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.

  14. Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  15. Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (HTG479)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

  16. How we support healthtech commissioning

    savings. Understand our different types of HealthTech guidance . View all NICE HealthTech guidance. Subscribe to NICE news for health...

  17. Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.

  18. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.

  19. Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)

    Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults

  20. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.

  21. Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

    Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults.

  22. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.

  23. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA795)

    Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.

  24. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

    Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.

  25. Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

    Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

  26. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  27. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

  28. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  29. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

  30. Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTG696)

    Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals.

  31. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (HTG339)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.

  32. Percutaneous endoscopic laser thoracic discectomy (HTG34)

    Evidence-based recommendations on percutaneous endoscopic laser thoracic discectomy. This involves using a laser to heat and destroy some of the inside of the disc and shrink the part that is sticking out.

  33. Open femoro–acetabular surgery for hip impingement syndrome (HTG270)

    Evidence-based recommendations on open femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.

  34. Computed tomography-guided thermocoagulation of osteoid osteoma (HTG27)

    Evidence-based recommendations on computed tomography-guided thermocoagulation of osteoid osteoma. This involves using high-frequency energy to heat the growth and destroy it.

  35. Endoscopic submucosal dissection of lower gastrointestinal lesions (HTG212)

    Evidence-based recommendations on endoscopic submucosal dissection of lower gastrointestinal lesions. This involves inserting a camera through the anus and injecting a solution to raise the affected area for removal.

  36. Lumbar subcutaneous shunt (HTG41)

    Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.

  37. Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (HTG480)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

  38. Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children (HTG47)

    Evidence-based recommendations on balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children. This involves using a balloon to widen the narrow area of the heart to let blood flow through it more easily.

  39. Supraorbital minicraniotomy for intracranial aneurysm (HTG52)

    Evidence-based recommendations on supraorbital minicraniotomy for intracranial aneurysm. This involves clipping or wrapping the aneurysm through a smaller opening made in the skull, above the eyebrow.

  40. Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (HTG558)

    Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.

  41. Transcranial magnetic stimulation for obsessive-compulsive disorder (HTG548)

    Evidence-based recommendations on transcranial magnetic stimulation for obsessive-compulsive disorder in adults. This involves pulsing electromagnetic energy through the skull to stimulate the brain.

  42. Airglove air warming system for venous access (MIB151)

    NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .

  43. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .

  44. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

  45. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment (HTG739)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.

  46. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.

  47. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .

  48. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  49. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  50. Faltering growth (QS197)

    This quality standard covers recognising and managing faltering growth in babies (aged up to 1 year) and preschool children (aged over 1 year). It describes high-quality care in priority areas for improvement.